Save statistic in. XLS format. PNG format. PDF format. Show details about this statistic. Exclusive Premium functionality. Register in seconds and access exclusive features. Full access: To this and over 1 million additional datasets Save Time: Downloads allow integration with your project Valid data: Access to all sources and background information. Exclusive Corporate feature. Corporate Account. Statista Accounts: Access All Statistics. Basic Account.
The ideal entry-level account for individual users. Corporate solution including all features. The most important statistics. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations.
The Animal Health segment develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.
Contact Info. United States. Executive Leadership. Kenneth C. Executive Chairman of the Board. Robert M. President, Chief Executive Officer, Director. Caroline Litchfield. Franklin K. Dean Y. President - Merck Research Laboratories. Although Fosamax is intended to prevent bone loss, the medication may cause a loss of bone density. Patients reported bone fractures, and some developed a condition known as osteonecrosis of the jaw ONJ which caused in a loss of jawbone tissue.
Hundreds of lawsuits were filed, claiming that Merck knew about the dangers of Fosamax and though many of the lawsuits were dismissed, court battles are still ongoing including a Supreme Court judgment which directed the lower courts reconsider a ruling that allowed lawsuits to go to trial. Attempts to add warnings to the Fosamax label have been largely rejected by the FDA and the drug remains available in both brand name and generic form.
Januvia sitagliptin is a newer medication for treating type 2 diabetes. It gained FDA approval in but like similar medications, has caused many different health problems for patients.
A related medication, Janumet, is a combination of sitagliptin and metformin and may also be responsible for a number of injuries. By , over patients had reported cases of pancreatitis as a result of Januvia. About 10 to 30 percent of these cases were fatal. Since then, hundreds of patients have reported pancreatic cancer and pancreatic disorder and patients, and their families have filed suit for compensation of these cases.
No settlements have been announced for any of the medications. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.
By continuing, you will be directed to a site intended only for residents of the United States and Canada. Ganirelix Acetate Injection Prescribing Information.
There are no products for this section. Contact us Report an adverse event.
0コメント